Drug Search Results
More Filters [+]

RDC-1036

Alternative Names: rdc-1036, rdc1036, rdc 1036
Latest Update: 2011-08-23
Latest Update Note: Clinical Trial Update

Product Description

For Opioid-induced Constipation (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01382797)

Mechanisms of Action: OPRM Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alkermes
Company Location: DUBLIN 4 L2 00000
Company CEO: Richard F. Pops
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for RDC-1036

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Constipation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ALK37-003

P2

Completed

Constipation

2010-12-01

Recent News Events

Date

Type

Title